FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

NCT03283761 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Gastro-Esophageal Junction Adenocarcinoma
Gastric Cancer

Interventions

DRUG: Nab-paclitaxel 150 mg/m^2
DRUG: Oxaliplatin 85 mg/m^2
DRUG: 5-FU 1200 mg/m^2 x 2 D
DRUG: Leucovorin 400 mg/m^2

Sponsor

Al B. Benson, III, MD

Collaborators

[object Object]
[object Object]